Wed, May 10, 2023

Nigel Dally Maintained (ARQT) at Buy with Decreased Target to $45 on, May 10th, 2023

-
Nigel Dally of Morgan Stanley, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Buy with Decreased Target from $47 to $45 on, May 10th, 2023.

Nigel has made no other calls on ARQT in the last 4 months.



There are 3 other peers that have a rating on ARQT. Out of the 3 peers that are also analyzing ARQT, 0 agree with Nigel's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Nigel


  • Serge Belanger of "Needham" Reiterated at Strong Buy and Held Target at $24 on, Wednesday, April 19th, 2023
  • Gregory Fraser of "Truist Securities" Maintained at Strong Buy with Decreased Target to $45 on, Wednesday, March 29th, 2023
  • Vikram Purohit of "Morgan Stanley" Maintained at Buy with Decreased Target to $50 on, Wednesday, March 1st, 2023
-